AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

C4 Therapeutics, Inc. Director's Dealing 2021

Dec 23, 2021

33861_dirs_2021-12-23_d948d248-a52b-4c3d-849b-ebe2e7808899.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-12-22

Reporting Person: Crystal Adam (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-22	Common Stock	M	5000	$6.49	Acquired	15000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-22	Stock Option (Right to Buy)	$6.49	M	5000	Disposed	2029-04-08	Common Stock (5000)	Direct

Footnotes

F1: 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter.